发明名称 Administration of growth factors for the treatment of CNS disorders
摘要 A method and system that is directed to the local delivery of growth factors to the mammalian CNS to treat CNS disorders associated with neuronal death and/or dysfunction is described.
申请公布号 US9050299(B2) 申请公布日期 2015.06.09
申请号 US201313781174 申请日期 2013.02.28
申请人 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 发明人 Bankiewicz Krystof S.
分类号 A61K38/00;A61K38/18;A61P3/04;A61P25/00;A61K9/00;A61K49/04;A61K49/18;A61K48/00;A61K33/24 主分类号 A61K38/00
代理机构 Bozicevic, Field & Francis LLP 代理人 Bozicevic, Field & Francis LLP ;Sherwood Pamela J.
主权项 1. A method of treating a human patient for Alzheimer's disease, comprising: administering to a target brain tissue of said patient a therapeutically effective amount of a pharmaceutical composition comprising a growth factor selected from: NGF, BDNF, NT-3, NT-4/5, NT-6, GDNF, CNTF, LIF, IGF-1, b-FGF, neurturin, persephin, artemin, TGFα, TGFβ, IGF-2, PDGF, EGF, cardiotropin, IGF, VEGF, Sonic hedgehog (SHH), BMP, FGF20, VIP, pleiotrophin (PTN), and HGF; wherein said growth factor is administered by intermittent convection enhanced delivery (CED) at a rate that counters the tissue clearance rate of said growth factor, wherein there is cessation of growth factor delivery during the intermissions between administrations, wherein the intermissions between administration of said growth factor are at least about one week, wherein said Alzheimer's disease is treated.
地址 Oakland CA US
您可能感兴趣的专利